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Topical Simvastatin as Host-
Directed Therapy against Severity 
of Cutaneous Leishmaniasis in Mice
Suraj P. Parihar1,2, Mary-Anne Hartley3, Ramona Hurdayal1,2,4, Reto Guler1,2 & 
Frank Brombacher1,2
We recently demonstrated that statins mediate protection against intracellular pathogens, 
Mycobacterium tuberculosis and Listeria monocytogenes in mice. Here, we investigated the 
immunomodulatory potential of simvastatin as a topical or systemic host-directed drug therapy in 
controlling inflammatory responses in an experimental mouse model of cutaneous leishmaniasis 
caused by Leishmania major (LV39). In an ear infection model, topical application of simvastatin directly 
on established lesions significantly reduced severity of the disease reflected by ear lesion size and 
ulceration. The host protective effect was further accompanied by decreased parasite burden in the ear 
and draining lymph nodes in both BALB/c and C57BL/6 mice. Pre-treatment of these mice on a low-fat 
cholesterol diet and systemic simvastatin also reduced footpad swelling, as well as parasite burdens 
and ulceration/necrosis in the more robust footpad infection model, demonstrating the prophylactic 
potential of simvastatin for cutaneous leishmaniasis. Mechanistically, following L. major infection, 
simvastatin-treated primary macrophages responded with significantly reduced cholesterol levels 
and increased production of hydrogen peroxide. Furthermore, simvastatin-treated macrophages 
displayed enhanced phagosome maturation, as revealed by increased LAMP-3 expression in fluorescent 
microscopy and Western blot analysis. These findings demonstrate that simvastatin treatment 
enhances host protection against L. major by increasing macrophage phagosome maturation and killing 
effector functions.
Leishmaniasis is a neglected human parasitic disease of the tropic. A haematophagous sand fly vectors the 
Leishmania parasite, and its numerous species give rise to a variety of clinical manifestations, ranging from 
localised, disfiguring inflammatory skin lesions to fatal visceral forms. Collectively, over 1.3 million people are 
infected worldwide1. To date, there are no effective vaccines and current first-line therapies are based on an anti-
quated arsenal of pathogen-directed drugs, such as pentavalent antimonials. These require long term intravenous 
therapy as well as monitoring for toxic side-effects2. Hence, there is a need for adjunctive compounds, which may 
improve the efficacy and longevity of existing anti-leishmanial drugs or control inflammatory pathology of the 
host responses3.
Host-directed immunotherapeutic have the major advantage of reducing the potential emergence of 
drug-resistance4 and may also interfere with the complex of immune evasion which Leishmania parasites has 
developed in order to promote its survival within the phagolysosome of host macrophages. One such evasion 
mechanism is the parasite’s ability to reduce macrophage activation by manipulating membrane cholesterol in 
host cells5. Statins are widely used cholesterol-lowering drugs, which target the key rate-limiting enzyme of the 
cholesterol biosynthesis pathway, hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase6. Statins are 
reported to exert pleiotropic immunomodulatory effects independent of their signature cholesterol-lowering 
properties7,8. For example, statins influence anti-inflammatory activity by decreasing MHC-II-mediated T-cell 
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activation9. In addition, statin therapy has been associated with reduced mortality in diseases that induce severe 
hyper-inflammation, such as bacteraemia10,11 and promotes a protective response against parasitic diseases such 
as Toxoplasma gondii12. Previously, we demonstrated that simvastatin has a beneficial effect on the prevention of 
murine listeriosis13 and tuberculosis in both mice and humans14. On the other hand, Contrasting reports have 
shown cholesterol depletion (or statin treatment) to be either beneficial5,15,16 or detrimental17,18 to the host during 
Leishmania infection.
In this study, we investigated the effect of simvastatin treatment on the pathogenesis of cutaneous leishmani-
asis caused by Leishmania. major LV39 parasites. We show a novel therapeutic potential for a topical application 
of simvastatin that reduces tissue damage and parasite burden in lesions caused by L. major. In addition, simvas-
tatin also displayed host protective effects when explored for its prophylactic potential, which reduced footpad 
swellings and parasite burdens in mice. Mechanistically, pre-treatment of primary macrophages with simvastatin 
resulted in increased production of hydrogen peroxide and phagosome maturation, leading to enhanced killing 
effector functions.
Results
Topical application of simvastatin on ear lesions caused by Leishmania major is therapeutic 
in both BALB/c and C57BL/6 mice. To investigate the effect of a topical application of simvastatin 
on the progression of cutaneous leishmaniasis in mice, we used a previously established murine ear-model of 
L. major infection (1 × 103)19. This model allowed us to generate practically accessible lesions on which the topical treat-
ment could be applied. The ear model is particularly sensitive to the quantity of parasites inoculated, where resistant 
C57BL/6 mice have poorly detectable signs of infection at low doses19. Thus, we used a low dose of 1 × 103 parasites for 
BALB/c only (Fig. 1) and a ten-fold higher dose of 1 × 104 parasites for both BALB/c and C57BL/6 (Fig. 2).
With 1×103 parasites  infection in BALB/c mice, we found that our daily regimen of topical simvastatin treat-
ment (Fig. 1a) resulted in visibly decreased ear swelling (Fig. 1b) and ulceration (Fig. 1g), which was further 
accompanied by reduced parasite burdens in the ear and cervical lymph nodes (LN) (Fig. 1c) after 10 weeks of 
infection. Interestingly, the treatment had no effect on the number of cells recruited to the draining LNs (Fig. 1d), 
nor was there any difference in the percentages of T and B-lymphocytes (Fig. 1e), or myeloid cells such as mac-
rophages, dendritic cells and neutrophils in the LN (Fig. 1f).
Topical treatment of simvastatin in BALB/c mice infected with a 10-fold higher inoculum (1 × 104) had almost 
identical results, with reduced lesion swelling (Fig. 2b) and ulceration (Fig. 2l). Furthermore, histological analysis 
using H&E staining revealed decreased tissue destruction in simvastatin-treated mice when compared to control 
animals (Fig. 2l). Again, treatment in BALB/c mice was also accompanied by reduced parasite loads in ear and drain-
ing cervical lymph nodes (Fig. 2c) and did not show any significant changes in cell numbers or percent immune cell 
recruitment (Fig. 2d–f). More interestingly, topical simvastatin was also able to show a protective effect in genetically 
resistant C57BL/6 mice (Fig. 2g), resulting in reduced parasite burden in lymph nodes (Fig. 2h) and no ulceration 
(Fig. 2m). Similar to BALB/c mice, no significant differences were found in cell numbers or percentages of immune 
cell populations recruited to the lymph nodes (Fig. 2i–k) however histological analysis using H&E staining revealed 
decreased tissue destruction in ear lesions of simvastatin-treated C57BL/6 mice (Fig. 2m). Together, these results 
demonstrate the potential use of simvastatin as a topical treatment for cutaneous leishmaniasis.
Systemic simvastatin treatment increased protection against L. major infection in both sus-
ceptible BALB/c and resistant C57BL/6 mice. We next examined whether the systemic administration 
of simvastatin could act as a prophylaxis or therapeutic against subsequent L. major (LV39, 2 × 106) infection. To 
this end, simvastatin was administered at 20 mg/kg via intraperitoneal injections every other day for two weeks 
before inoculation in the hind footpad as shown in the layout (Fig. 3a). Similar to topical application, we observed 
that simvastatin treated BALB/c and C57BL/6 mice had significantly reduced footpad swelling, maintained up to 
8 weeks of infection (Fig. 3b). Further, parasite loads in both footpads and draining popliteal lymph nodes were 
significantly reduced when compared to control mice (Fig. 3c). Next, we investigated the therapeutic potential 
of simvastatin by treating mice after 3 weeks of L. major infection as shown in the layout (Fig. 3d). We found no 
effect of simvastatin on footpad swelling in BALB/c mice however, slight differences were observed in C57BL/6 
mice (Fig. 3e). Despite the slight differences in footpad swelling, interestingly post-treatment with simvastatin 
decreased the parasite burden in footpads and popliteal lymph nodes in both BALB/c and C57BL/6 mice (Fig. 3f). 
As in our previous results using topical simvastatin, percentages of cell recruitment and total cell numbers har-
vested from lymph nodes in both BALB/c (Fig. 4a,b) and C57BL/6 (Fig. 4c,d) mice were unaffected following 
pre-treatment. Also mirroring the topical treatment, we found no major differences in cytokine production such 
as IFN-γ and IL-10 between systemically simvastatin-treated and control in both BALB/c (Fig. 4b) and C57BL/6 
(Fig. 4d) mice. This suggests that simvastatin treatment had no effect on the cytokine production during L. major 
infection. Similarly, serum SLA-specific antibody responses were unaffected during systemic simvastatin treat-
ment in both BALB/c and C57BL/6 mice (data not shown). Taken together, these results suggest that systemic 
administration of simvastatin increases host protective immune responses against L. major infection in both 
BALB/c and C57BL/6 mice, and this enhanced immunity was not mediated by cellular recruitment to the drain-
ing lymph nodes or by T-cell cytokine production.
Simvastatin reduces macrophage parasite burden by enhancing oxidative burst. To investi-
gate the cell intrinsic effect of simvastatin treatment on the internalisation and persistence of L. major, murine 
macrophages were pre-treated with simvastatin. Parasite growth determined at 24 hours post infection (Fig. 5a) 
showed a significantly reduced parasite burden in macrophages pre-treated with a concentration of 100 μ M of 
simvastatin by limiting dilution assay. In contrast to the pre-treatment strategy, post-treatment of macrophages 
with simvastatin following L. major infection had no effect on parasite growth in comparison to control cells 
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(data not shown). We confirmed pre-treatment findings by infecting macrophages with GFP-expressing L. major 
IL81 parasites and subsequently enumerating them in macrophages using fluorescent microscopy (Fig. 5b). The 
reduced parasitic growth in macrophages was not due to a cytotoxic effect of the drug, as shown by a viability 
MTT assay (Fig. 5c) nor due to effect on parasite uptake after 24 hours of infection (data not shown). Oppositely, 
macrophages cultured with the cholesterol-precursor, mevalonate, increased parasite growth (Fig. 5d), which 
suggested that the parasitotoxic effect of simvastatin was a result of its inhibitory action on the cholesterol biosyn-
thesis pathway. Indeed, simvastatin treatment was associated with decreased cholesterol content in BMDMs when 
compared to control cell lysates (Fig. 5e). Moreover, simvastatin-treated BMDMs displayed significantly higher 
levels of hydrogen peroxide than control macrophages at 24 hours post infection (Fig. 5f). As it has been shown 
that hydrogen peroxide kills Leishmania parasites in wild type macrophages20, this finding highlights a potential 
mechanism for the anti-leishmanial effect of simvastatin. Thus, simvastatin-treated macrophages have reduced 
parasite burden, which may be due to simvastatin-dependent enhancement of host oxidative killing functions.
Simvastatin increased phagosome maturation in Leishmania-infected macrophages. As an 
evasion mechanism, Leishmania parasites can block phagosome maturation21 and thereby promote its survival 
within macrophages. In addition, it has been reported that induction of host autophagy increases parasite loads 
in BALB/c mice but not in C57BL/6 mice22. We hypothesised that simvastatin promotes the maturation of pha-
gosomes thereby increasing macrophage-mediated killing of the parasites. We analysed two phagosome markers 
(LAMP-3 and Cathepsin D) and a marker for autophagy (LC3-II) in macrophages following L. major (GFP-IL81) 
Figure 1. Topical application of simvastatin improves control of Leishmania major at low dose infection 
in BALB/c mice. (a) BALB/c mice were infected subcutaneously in the ear dermis with 1 × 103 stationary 
phase L. major LV39 (MRHO/SV/59/P) promastigotes. On the appearance of lesions, ears were treated daily 
for 7 weeks with topically applied simvastatin (or vehicle control) as shown in the layout. (b) Ear swelling was 
measured weekly. (c) Mice were sacrificed to measure parasite burden in the ear dermis and in cervical lymph 
nodes by limiting dilution assay after 10 weeks of infection. (d) Cell numbers recovered from cervical lymph 
nodes. (e) Percentages of lymphocyte populations and (f) myeloid cells. The surface markers used to determine 
the leukocyte phenotypes are as follows; B cells = CD19+ CD3−, CD4 = CD3+ CD4+, CD8 = CD3+ CD8+, 
Mphs = CD11b+ MHCII+ CD11c−, DCs = CD11c+ MHCII+ and Neutrophils = Gr1+ CD11c−.  
(g) Photographs of simvastatin-treated mice displaying reduced lesion size and inflammation. Results are the 
mean ± SEM of n = 5 mice/group from one experiment, where N denotes the necrotic ear lesions. Statistical 
analysis was performed defining differences to vehicle treated control mice as significant (*p < 0.05; **p < 0.01; 
***p < 0.001).
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infection. Indeed, after 24 hours of infection, simvastatin treated macrophages exhibited an increase in the 
expression of LAMP-3 and Cathepsin D. However, simvastatin treatment had no effect on LC3-II induction, as 
demonstrated by qualitative confocal microscopy (Fig. 5g). Results from confocal microscopy were further con-
firmed by Western Blot analysis and densitometry, where LAMP-3 was increased, but LC3-II remained unaffected 
(Fig. 5h,i). Together, these results suggest that simvastatin treatment mediates phagosome maturation thereby 
increasing the clearance of Leishmania parasites in macrophages.
Discussion
Here, we demonstrated that host cholesterol biosynthesis plays a role in the pathogenesis of cutaneous leishma-
niasis. The inhibition of cholesterol biosynthesis by simvastatin, (which targets the host HMG-CoA reductase) 
reduced the growth of intracellular Leishmania major parasites in primary macrophages as well as in an in vivo 
mouse model (ear and footpad) of infection in both BALB/c and C57BL/6 mice.
Figure 2. Topical application of simvastatin increases host protection against 10-fold high dose L. major 
infection in both BALB/c and C57BL/6 mice. (a) BALB/c and C57BL/6 mice were infected subcutaneously 
in the dermis of the ear with high dose (1 × 104) stationary phase L. major LV39 promastigotes. Following 
the eruption of lesions, ears were treated daily for 6 weeks (BALB/c) and 5 weeks (C57BL/6) with topically 
applied simvastatin (or vehicle control) as shown in the layout. (b) BALB/c ear swelling was measured weekly. 
(c) Parasite burden in ear and cervical lymph nodes was determined by limiting dilution assay after 9 weeks of 
infection. (d) Cell numbers recovered and (e,f) the percentage of immune cell populations in cervical lymph 
nodes. (g) C57BL/6 ear swelling and (h) parasite burden in lymph nodes were measured after 8 weeks of 
infection. (i–k) Cell numbers recovered and percentage cell populations from lymph nodes. Representative 
images and H&E stained (l) BALB/c and (m) C57Bl/6 ears after 9 weeks and 8 weeks of infection, respectively. 
Results are the mean ± SEM of n = 5 mice/group and representative of two independent experiments (BALB/c) 
and n = 6 mice/group from one experiment (C57BL/6), where N denotes the necrotic ear lesions. Statistical 
analysis was performed defining differences to vehicle treated control mice as significant (*p < 0.05; **p < 0.01; 
***p < 0.001).
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In an effort to investigate the effect of simvastatin as a therapeutic agent at the site of infection, we explored 
a more practical topical administration of simvastatin directly on cutaneous ear lesions. Our results showed a 
significant improvement in presentation of the disease in both simvastatin-treated C57BL/6 and BALB/c mice. 
Local application of simvastatin has been used in the field of wound healing, where topical simvastatin pro-
moted the resolution of Staphylococcus aureus-inoculated cutaneous wounds in mice23. A recent study built on 
this evidence, reporting that reduced inflammatory cytokines and bacterial burdens in the wounds caused by 
methicillin-resistant S. aureus (MRSA) in BALB/c mice, was due to the ability of simvastatin to suppress bac-
terial biofilm formation as well as the synthesis of proteins and MRSA toxins24. Another study highlighted the 
immunomodulatory role of statins in wound healing where the topical application of atorvastatin on traumatic 
lesions in rats (8 mm biopsy punch) resulted in accelerated tissue repair25. Consistence with these findings, topi-
cal simvastatin in our ear infection model of L. major also reduced lesion size and intra-lesion parasite burdens. 
However, more surprising and important was that topical treatment was also able to decrease parasite loads in 
draining cervical lymph nodes.
Besides, reduced severity of disease by topical application of simvastatin in ear infection model, we also 
found that systemic treatment with simvastatin before L. major infection (prophylactic) was protective in both 
the resistant C57BL/6 as well as the susceptible BALB/c mice as host-directed agent during footpad infection. 
The improved disease outcome in animals was independent of Th1 cytokines, type1 antibody production and 
host genetic background. Furthermore, simvastatin treatment after L. major infection (therapeutic) had no major 
effect on inflammatory response in footpads of the animals. Interestingly, this strategy also controlled parasite 
Figure 3. Systemic administration of simvastatin reduces the severity of subsequent L. major infection 
both in BALB/c and C57BL/6 mice. (a) Mice were fed a low-fat cholesterol diet (LFCD) or normal chow diet 
for three weeks. In the second and third weeks, mice treated every second day with intra-peritoneal injections 
of either simvastatin or vehicle control. At the end of treatment, mice were infected in the hind footpad with 
2 × 106 stationary phase metacyclic L. major LV39 parasites as shown in the layout. (b) Footpad swelling in 
BALB/c and C57BL/6 mice was measured to monitor disease progression at weekly intervals. (c) Parasite 
burdens in footpads and draining popliteal lymph nodes was determined by limiting dilution assay after 8 weeks 
of infection. Data represents the mean of four pooled independent experiments (n = 21–22 mice/group). (d) 
Mice were infected with L. major parasites as in (a), after 3 weeks of infection mice were treated with simvastatin 
for two weeks via intraperitoneal injections and fed on LFCD as shown in the layout. (e) Footpad swelling was 
monitored in BALB/c and C57BL/6 mice. (f) Parasite burdens were measured in footpads and popliteal lymph 
nodes after 7 weeks of infection. Data represented as mean ± SEM of n = 5–6 mice/group from one experiment, 
where N denotes the necrotic footpad lesions. Statistical analysis was performed defining differences to vehicle 
treated control mice as significant (*p < 0.05; **p < 0.01; ***p < 0.001).
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burdens in footpads and draining lymph nodes further suggesting that immunomodulatory function of simvas-
tatin restricted parasite burdens at cellular level. In contrast to our findings, a study demonstrated that lovastatin 
treated mice had no significant difference in footpad swelling or parasite burdens when challenged with L. major 
at 5 weeks post infection18. This difference might be attributed to the use of activated lovastatin, being a less potent 
statin than simvastatin, an early time point analyzed and mice were fed on a normal chow diet.
Oppositely, the beneficial role of pravastatin was previously demonstrated in increased survival of 
 L. amazonensis-infected susceptible BALB/c mice, but not in the survival of C57BL/6 mice after 50 weeks of infection15, 
indicating that the effect may depend on underlying immune and genetic biases within the host. The same authors 
reported that pravastatin treated BALB/c and C57BL/6 mice displayed reduced footpad swelling in L. amazonensis 
infection16 with pravastatin-treated peritoneal macrophages from BALB/c mice showing increased macrophage killing 
effector functions16. Since statins are known to act independently of their cholesterol-lowering properties7, the observed 
outcome of cutaneous leishmaniasis in this study might be due to the modulation of intermediates of the mevalonate 
pathway, which are targeted by simvastatin.
In terms of host cholesterol modulation in leishmaniasis, it appears from our findings and others that hypo-
cholesterolemia induced by statins is important in decreasing the presentation of cutaneous form of disease in 
mice. In contrast, hypercholesterolemia induced either extrinsically (atherogenic/high fat diet) or intrinsically 
by deletion of apolipoprotein E gene (apoE−/− mice), is crucial for increased host protection against visceral 
L. donovani infection in mice17. This suggests cholesterol plays a differential role in the pathogenesis of cutaneous 
and visceral forms of leishmaniasis.
Perhaps more interesting is that the observed reduction in parasite growth might be a direct effect of statins 
on the L. major HMG-CoA reductase26. Several other studies have reported a direct anti-fungal role for statins 
in extracellular culture27–29. In contrast, we observed no effect on extracellular growth of L. major promastigote 
parasites in presence of simvastatin at various concentrations tested (data not shown). Thus, the prophylactic and 
therapeutic effect of our treatment strategies might function by targeting HMG-CoA reductase in the host, which 
could disrupt the complex pathways of immune evasion that permit parasite survival and persistence.
Figure 4. Simvastatin treatment has no effect on immune cell populations and cytokine production during 
L. major infection in both BALB/c and C57BL/6 mice. (a,c) Panels represents the percentage of immune 
cell populations (B cells, T cells, macrophages, DCs and neutrophils) and T effector and central memory cells 
recovered from lymph nodes in BALB/c (a) and C57BL/6 (c) mice following L. major LV39 infection. (b,d) 
Panels represents IFN-γ and IL-10 production in total lymph node cells (2 × 106) re-stimulated ex vivo with 
Soluble Leishmania Antigen (SLA) and plate bound anti-CD3 by ELISA. Additionally, these panels show cell 
numbers recovered in lymph nodes of BALB/c and C57BL/6 mice after 8 weeks of infection. Results are the 
mean ± SEM of n = 5 mice/group and representative of two independent experiments. Statistical analysis was 
performed defining differences to vehicle treated control mice as significant (*p < 0.05).
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Finally, an important mechanism of immune evasion by Leishmania parasites is their ability to suppress 
phagolysosome fusion, thereby creating a safe haven within macrophages to enable its persistence and growth21. 
We demonstrate a role for simvastatin in rescuing Leishmania-induced suppression of phagosome maturation 
(LAMP-3), thereby decreasing parasitic loads. Interestingly, in this study autophagy remained unaffected in 
Leishmania-infected macrophages, in contrast to Mtb-infected macrophages as we described previously14, sug-
gesting that the simvastatin-mediated effect on autophagy may be pathogen-specific. This could also be due to 
the fact that autophagy (LC3-II) during Leishmania infection is dependent on the host genetic background22. 
Another well-known immune evasion strategy deployed by Leishmania parasites is to avoid microbicidal func-
tions such as oxidative burst of peroxides30. Our finding demonstrated that simvastatin-mediate increased pro-
duction of hydrogen peroxide upon infection, which would aid the clearance of intracellular Leishmania parasites.
In summary, our findings reveal the therapeutic and prophylactic potential of simvastatin in experimen-
tal murine models of cutaneous leishmaniasis. Our mechanistic studies add to the growing literature on the 
Figure 5. Simvastatin treatment in primary macrophages decreases parasite loads and enhances both 
hydrogen peroxide radical production and phagosome maturation. (a,b) Bone marrow-derived macrophages 
were treated with varying concentration of simvastatin before infection with L. major parasite (MOI: 10:1), 
parasite burden was assessed 24 hours post-infection by (a) limiting dilution assay and (b) number of GFP-
expressing L. major (IL81) parasites. (c) Macrophages were treated with varying concentration of simvastatin 
to measure cell viability by MTT assay after 48 hours. (d) Mevalonate treatment rescues the inhibitory effect 
of simvastatin on parasite burdens in macrophages. (e) Simvastatin treatment reduces intracellular cholesterol 
levels in L. major-infected macrophages. (f) Simvastatin treatment increased the production of hydrogen 
peroxide (H2O2) in infected macrophages. (g) Confocal images of macrophages treated with simvastatin and 
infected with GFP-expressing IL81 L. major parasites. Phagosome and autophagy markers are indicated on the 
panels, IL81 L. major parasites are shown as green, LAMP-3, Cathepsin D and LC3-II are red and the DAPI 
stained nucleus is blue. (h,i) Western blot and densitometry showed significant increase in phagosome (LAMP-
3) marker in total macrophage cell lysates upon L. major infection. Results are the mean ± SEM of triplicates 
and are representative of two independent experiments (*p < 0.05; **p < 0.01; ****p < 0.0001).
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immunomodulatory actions of statins, providing an interesting avenue for adjunctive drug development in cuta-
neous leishmaniasis.
Methods
Mice. BALB/c and C57BL/6 mice (8–10 weeks) were maintained under specific-pathogen-free conditions in 
individually ventilated cages at the University of Cape Town, Animal Research Facility. All experiments were 
performed in accordance with the South African National Guidelines and University of Cape Town practice for 
laboratory animal procedures. The protocol (AEC: 012/033) was approved by the Animal Ethics Committee, 
Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Reconstitution of simvastatin. Simvastatin (Sigma-Aldrich) was reconstituted in 1% DMSO with PBS at 
10 mg/ml. Drug was then diluted 10 times in PBS to achieve 1 mg/ml concentration. In parallel, vehicle control 
was prepared without drug, which resulted in final concentration of 0.1% DMSO in PBS. During optimization in 
our previously published studies using simvastatin13,14, we found that vehicle control revealed no difference when 
compared to PBS, hence in the present study PBS group was not included.
Topical application of simvastatin on the lesions caused by Leishmania major infection. Mice 
were infected subcutaneously in the dermis of the ear with 1 × 104 (high dose) or 1 × 103 (low dose) stationary phase L. 
major LV39 (MRHO/SV/59/P). L. major parasite strain was maintained by continuous passage in BALB/c mice as pre-
viously described31. On the first appearance of ear lesions, ears were treated daily for 6–8 weeks with topically applied 
simvastatin (20 μ g/10 μ l) or vehicle control (0.1% DMSO in PBS), immobilizing the mouse until the preparation was 
absorbed. Disease progression was assessed by measuring the ear lesion diameter weekly using a Vernier calliper.
Systemic treatment of simvastatin before L. major infection. Mice were fed on low fat cholesterol 
diet (LFCD) or normal chow for three weeks. After one week, mice were intraperitoneally injected with 20 mg/kg 
of simvastatin every other day, for two weeks (whilst mice on normal chow were injected with vehicle control). 
After the 2-week treatment, anesthetized mice were subcutaneously infected in the left hind footpad with 2 × 106 
stationary phase L. major LV39 promastigotes. All mice were fed on normal chow after infection. Footpad 
swelling was measured weekly using a Mitutoyo micrometer gauge (Brütsch, Zürich, Switzerland). At 8 weeks 
post-infection, the infected footpads and draining popliteal lymph nodes were then collected for detection of 
viable parasites by limiting dilution assay31.
Generation of bone marrow-derived macrophages (BMDMs) and in vitro infection with 
L. major. Bone marrow-derived macrophages (BMDMs) were generated from progenitor bone-marrow cells 
from 8 week old C57BL/6 mice as described previously14. BMDMs (2 × 105) were then cultured in the presence of 
various concentrations of simvastatin or vehicle alone (0.004% DMSO final) overnight at 37 °C in 5% CO2 incuba-
tor. Cells were then infected with L. major LV39 parasites at an MOI of 10 parasites per macrophage for 24 hours 
at 37 °C followed by two washes with pre-warmed DMEM to remove non-internalized parasites. The detection 
of viable, phagocytosed parasites were determined by two-fold limiting dilution assay of lysed macrophages32.
Cell viability assay. Cell viability of simvastatin-treated BMDMs was quantified using a colorimetric assay 
whereby the yellow tetrazolium salt MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) is reduced 
to a purple formazan by the mitochondrial enzymes of living cells. Macrophages (2 × 105) were treated with simvastatin 
as above. 10 μ l of MTT (5 mg/ml) was added and incubated, at 37 °C for 2 hours. This mixture was then solubilised in 
0.04N HCL in isopropanol and incubated on a shaker for 30 min before the absorbance was read at 570 nm14.
Measurements of macrophage cholesterol content and hydrogen peroxide. Simvastatin treated 
macrophages were infected with L. major (LV39) at an MOI of 10 for 24 hours or left uninfected. Cholesterol 
content was analysed in total macrophage cell lysates (3 × 106), using a cholesterol assay kit (Bioassay system)18. 
Release of hydrogen peroxide (H2O2) from macrophages (2 × 105) was measured using a colorimetric detection 
kit (Amplex Red Hydrogen peroxide assay kit, Molecular Probes)16.
Fluorescence microscopy. Macrophages were seeded on coverslips and treated with 100 μ M simvastatin 
overnight as above. Cells were then infected with green fluorescent protein (GFP) expressing- L. major (IL81) 
GFP-IL81 (MHOM/IL/81/FEBNI) at MOI of 10. After 24 hours, cells were washed and fixed in 4% paraform-
aldehyde followed by labelling of phagosome markers with fluorescent antibodies against Lysosome Associated 
Membrane Protein-3 (LAMP-3, Santa Cruz) and a lysosomal protease (Cathepsin D, Santa Cruz). Macrophages 
were also labelled for Light Chain 3-II (LC3-II, Santa Cruz), a marker for autophagy. These markers were then 
visualized by counter-stained with Alexa 546 antibodies (Molecular probes, Invitrogen) followed by nuclear stain 
(DAPI). Coverslips were then mounted using mowiol-containing anti-fade on glass slides. Images were captured 
under Carl Zeiss 510 confocal microscope and analysed using Zen Blue software as previously described14.
Western Blot Analysis. SDS-PAGE and Western Blot analysis was performed as previously described14. 
Briefly, macrophages (3 × 106) were treated simvastatin (100 μ M) as above and then infected with L. major 
(LV39) at MOI of 10 parasites per macrophage. After 24 hours, cells were washed with pre-warmed medium 
to remove extracellular parasites. Macrophages were then lysed with ice-cold RIPA buffer containing protease 
inhibitor for 30 minutes at 4 °C. Total cell lysates were collected and analysed for protein content using BCA assay 
(ThermoFisher). Cell lysates with equilibrated protein volume (40 μ g) were electrophoresed on 12% SDS-PAGE 
gel and then transferred to a nitrocellulose membrane (Sigma). The membrane was probed with anti-LAMP-3, 
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Cathepsin D and LC3-II primary antibodies diluted (1:200) in blocking buffer at 4 °C overnight. Membrane was 
then incubated with an HRP-conjugated secondary antibody (1:10,000) for 1 hour at room temperature in block-
ing buffer. Immunoblots were developed using Super Signal West Dura substrate (Pierce).
Statistical Analysis. All data were analysed using Graphpad Prism v 6.0, a unpaired student t-test (two-tailed 
with unequal variance). A ‘p’ value of less than 0.05 was considered significant.
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